Amylyx Pharmaceuticals, Inc.
AMLX
$15.01
-$0.75-4.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.34% | -100.08% | -100.32% | -77.06% | -33.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.34% | -100.08% | -100.32% | -77.06% | -33.22% |
| Cost of Revenue | -64.60% | -65.51% | -64.71% | 48.88% | 108.10% |
| Gross Profit | -45.80% | -471.35% | -182.01% | -162.22% | -137.59% |
| SG&A Expenses | -56.79% | -63.27% | -64.25% | -39.30% | -15.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.91% | -56.64% | -56.96% | 10.90% | 35.64% |
| Operating Income | 9.17% | -27.15% | -155.37% | -852.23% | -2,658.43% |
| Income Before Tax | 41.78% | -15.93% | -234.30% | -656.45% | -4,620.35% |
| Income Tax Expenses | -131.96% | -118.12% | -111.68% | -107.82% | -48.52% |
| Earnings from Continuing Operations | 42.47% | -13.10% | -207.84% | -712.42% | -14,232.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.47% | -13.10% | -207.84% | -712.42% | -14,232.14% |
| EBIT | 9.17% | -27.15% | -155.37% | -852.23% | -2,658.43% |
| EBITDA | 9.00% | -27.64% | -158.26% | -829.45% | -3,038.60% |
| EPS Basic | 52.85% | -2.45% | -197.69% | -705.81% | -42,510.00% |
| Normalized Basic EPS | 19.13% | -20.43% | -162.95% | -743.83% | -8,814.09% |
| EPS Diluted | 52.86% | -2.00% | -189.63% | -734.04% | -16,355.60% |
| Normalized Diluted EPS | 19.09% | -19.89% | -157.20% | -770.19% | -38,426.00% |
| Average Basic Shares Outstanding | 24.09% | 15.08% | 7.59% | 1.41% | 1.73% |
| Average Diluted Shares Outstanding | 23.28% | 13.35% | 4.87% | -2.63% | -1.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |